Targeting HIF-1 for cancer therapy - PubMed (original) (raw)

Review

doi: 10.1038/nrc1187.

Affiliations

• PMID: 13130303
• DOI: 10.1038/nrc1187

Review

Targeting HIF-1 for cancer therapy

Gregg L Semenza. Nat Rev Cancer. 2003 Oct.

Abstract

Hypoxia-inducible factor 1 (HIF-1) activates the transcription of genes that are involved in crucial aspects of cancer biology, including angiogenesis, cell survival, glucose metabolism and invasion. Intratumoral hypoxia and genetic alterations can lead to HIF-1alpha overexpression, which has been associated with increased patient mortality in several cancer types. In preclinical studies, inhibition of HIF-1 activity has marked effects on tumour growth. Efforts are underway to identify inhibitors of HIF-1 and to test their efficacy as anticancer therapeutics.

PubMed Disclaimer

Similar articles

• Hypoxia-inducible factor 1 (HIF-1) in cancer.
  Quintero M, Mackenzie N, Brennan PA. Quintero M, et al. Eur J Surg Oncol. 2004 Jun;30(5):465-8. doi: 10.1016/j.ejso.2004.03.008. Eur J Surg Oncol. 2004. PMID: 15135470 Review.
• Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1.
  Krishnamachary B, Berg-Dixon S, Kelly B, Agani F, Feldser D, Ferreira G, Iyer N, LaRusch J, Pak B, Taghavi P, Semenza GL. Krishnamachary B, et al. Cancer Res. 2003 Mar 1;63(5):1138-43. Cancer Res. 2003. PMID: 12615733
• [The hypoxia-inducible factor HIF as a new target in cancer research].
  L'Allemain G. L'Allemain G. Bull Cancer. 2002 Mar;89(3):257-60. Bull Cancer. 2002. PMID: 11940464 Review. French.
• Hypoxia-inducible factors and hypoxic cell death in tumour physiology.
  Bacon AL, Harris AL. Bacon AL, et al. Ann Med. 2004;36(7):530-9. doi: 10.1080/07853890410018231. Ann Med. 2004. PMID: 15513303 Review.

Cited by

• Multi-omics reveals lactylation-driven regulatory mechanisms promoting tumor progression in oral squamous cell carcinoma.
  Jing F, Zhu L, Zhang J, Zhou X, Bai J, Li X, Zhang H, Li T. Jing F, et al. Genome Biol. 2024 Oct 15;25(1):272. doi: 10.1186/s13059-024-03383-8. Genome Biol. 2024. PMID: 39407253
• Master Role of Hypoxia in Cancer Progression: Major Insights During ISOTT's Half-Century.
  Vaupel P, Semenza GL. Vaupel P, et al. Adv Exp Med Biol. 2024;1463:15-20. doi: 10.1007/978-3-031-67458-7_3. Adv Exp Med Biol. 2024. PMID: 39400793 Review.
• Hypoxia-induced DTL promotes the proliferation, metastasis, and sorafenib resistance of hepatocellular carcinoma through ubiquitin-mediated degradation of SLTM and subsequent Notch pathway activation.
  Chen ZX, Mu MY, Yang G, Qi H, Fu XB, Wang GS, Jiang WW, Huang BJ, Gao F. Chen ZX, et al. Cell Death Dis. 2024 Oct 9;15(10):734. doi: 10.1038/s41419-024-07089-4. Cell Death Dis. 2024. PMID: 39384740 Free PMC article.
• Two-dimensional coordination risedronate-manganese nanobelts as adjuvant for cancer radiotherapy and immunotherapy.
  Huang Z, Huang S, Song S, Ding Y, Zhou H, Zhang S, Weng L, Zhang Y, Hu Y, Yuan A, Dai Y, Luo Z, Wang L. Huang Z, et al. Nat Commun. 2024 Oct 8;15(1):8692. doi: 10.1038/s41467-024-53084-w. Nat Commun. 2024. PMID: 39375342 Free PMC article.
• Lactate's impact on immune cells in sepsis: unraveling the complex interplay.
  Zhang T, Chen L, Kueth G, Shao E, Wang X, Ha T, Williams DL, Li C, Fan M, Yang K. Zhang T, et al. Front Immunol. 2024 Sep 20;15:1483400. doi: 10.3389/fimmu.2024.1483400. eCollection 2024. Front Immunol. 2024. PMID: 39372401 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations